Search

Your search keyword '"Willekens, Christophe"' showing total 133 results
Start Over Author "Willekens, Christophe" Language english
133 results on '"Willekens, Christophe"'

2. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Author

Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, and Kroemer, Guido

Published
2024
Full Text
View/download PDF

3. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

Author

Hermine, Olivier, Mariette, Xavier, Ravaud, Philippe, Bureau, Serge, Dougados, Maxime, Resche-Rigon, Matthieu, Tharaux, Pierre-Louis, Tibi, Annick, Azoulay, Elie, Cadranel, Jacques, Emmerich, Joseph, Fartoukh, Muriel, Guidet, Bertrand, Humbert, Marc, Lacombe, Karine, Mahevas, Matthieu, Pene, Frédéric, Porcher, Raphaël, Pourchet-Martinez, Valerie, Schlemmer, Frédéric, Yazdanpanah, Yazdan, Baron, Gabriel, Perrodeau, Elodie, Vanhoye, Damien, Kedzia, Cécile, Demerville, Lauren, Gysembergh-Houal, Anne, Bourgoin, Alexandre, Raked, Nabil, Mameri, Lakhdar, Montlahuc, Claire, Biard, Lucie, Alary, St.phanie, Hamiria, Samir, Bariz, Thinhinane, Semri, Hala, Hai, Dhiaa Meriem, Benafla, Moustafa, Belloul, Mohamed, Vauboin, Pernelle, Flamand, Saskia, Pacheco, Claire, Walter-Petrich, Anouk, Stan, Emilia, Benarab, Souad, Nyanou, Corine, Charreteur, Robin, Dupre, Céline, Cardet, Kévin, Lehmann, Blandine, Baghli, Kamyl, Madelaine, Claire, D'Ortenzio, Eric, Puéchal, Oriane, Semaille, Caroline, Savale, Laurent, Harrois, Anatole, Figueiredo, Samy, Duranteau, Jacques, Anguel, Nadia, Pavot, Arthur, Monnet, Xavier, Richard, Christian, Teboul, Jean-Louis, Durand, Philippe, Tissieres, Pierre, Jevnikar, Mitja, Montani, David, Pavy, Stephan, Nocturne, Gaétane, Bitoun, Samuel, Noel, Nicolas, Lambotte, Olivier, Escaut, Lelia, Jauréguiberry, Stephane, Baudry, Elodie, Verny, Christiane, Lefevre, Edouard, Zaidan, Mohamad, Molinari, Domitille, Leprun, Gaël, Fourreau, Alain, Cylly, Laurent, Grimaldi, Lamiae, Virlouvet, Myriam, Meftali, Ramdane, Fabre, Soléne, Licois, Marion, Mamoune, Asmaa, Boudali, Yacine, Le Tiec, Clotilde, Verstuyft, Céline, Roques, Anne-Marie, Georgin-Lavialle, Sophie, Senet, Patricia, Pialoux, Gilles, Soria, Angele, Parrot, Antoine, François, Helene, Rozensztajn, Nathalie, Blin, Emmanuelle, Choinier, Pascaline, Camuset, Juliette, Rech, Jean-Simon, Canellas, Antony, Rolland-Debord, Camille, Lemarié, Nadege, Belaube, Nicolas, Nadal, Marine, Siguier, Martin, Petit-Hoang, Camille, Chas, Julie, Drouet, Elodie, Lemoine, Matthieu, Phibel, Audrey, Aunay, Lucie, Bertrand, Eliane, Ravato, Sylviane, Vayssettes, Marie, Adda, Anne, Wilpotte, Celine, Thibaut, Pélagie, Fillon, Julie, Debrix, Isabelle, Fellahi, Soraya, Bastard, Jean-Philippe, Lefévre, Guillaume, Gottenberg, Jacques-Eric, Hansmann, Yves, Blanc, Frédéric, Ohlmann-Caillard, Sophie, Castelain, Vincent, Chatelus, Emmanuel, Chatron, Eva, Collange, Olivier, Danion, François, De Blay, Frédéric, Diemunsch, Pierre, Diemunsch, Sophie, Felten, Renaud, Goichot, Bernard, Greigert, Valentin, Guffroy, Aurelien, Heger, Bob, Kaeuffer, Charlotte, Kassegne, Loic, Korganow, Anne Sophie, Le Borgne, Pierrick, Lefebvre, Nicolas, Mertes, Paul-Michel, Noll, Eric, Oberlin, Mathieu, Poindron, Vincent, Pottecher, Julien, Ruch, Yvon, Weill, François, Meyer, Nicolas, Andres, Emmanuel, Demonsant, Eric, Tayebi, Hakim, Nisand, Gabriel, Brin, Stéphane, Sublon, Cédric, Becker, Guillaume, Hutt, Anne, Martin, Tristan, Bayer, Sophie, Metzger, Catherine, Mekinian, Arsene, Abisror, Noémie, Adedjouma, Amir, Bollens, Diane, Bonneton, Marion, Bourcicaux, Nathalie, Bourrier, Anne, Thibault Chiarabiani, Maria Chauchard, Chopin, Doroth.e, Cohen, Jonathan, Devred, Ines, Donadille, Bruno, Fain, Olivier, Hariri, Geoffrey, Jachiet, Vincent, Ingliz, Patrick, Garnier, Marc, Gatfosse, Marc, Ghrenassia, Etienne, Gobert, Delphine, Krause le Garrec, Jessica, Landman, Cecilia, Lavillegrand, Jean Remy, Lefebvre, Benedicte, Mahevas, Thibault, Mazerand, Sandie, Meynard, Jean Luc, Morgand, Marjolaine, Ouaz.ne, Zineb, Pacanowski, Jerome, Riviere, S.bastien, Seksik, Philippe, Sokol, Harry, Soliman, Heithem, Valin, Nadia, Urbina, Thomas, McAvoy, Chloé, Miranda, Maria Pereira, Aratus, Gladys, Berard, Laurence, Simon, Tabassome, Nguyen, Anne Daguenel, Girault, Elise, Mayala-Kanda, Cl.mentine, Antignac, Marie, Leplay, Céline, Arlet, Jean-Benoit, Diehl, Jean-Luc, Bellenfant, Florence, Blanchard, Anne, Buffet, Alexandre, Cholley, Bernard, Fayol, Antoine, Flamarion, Edouard, Godier, Anne, Gorget, Thomas, Hamada, Sophie-Rym, Hauw-Berlemont, Caroline, Hulot, Jean-Sébastien, Lebeaux, David, Livrozet, Marine, Michon, Adrien, Neuschwander, Arthur, Pennet, Marie-Aude, Planquette, Benjamin, Ranque, Brigitte, Sanchez, Olivier, Volle, Geoffroy, Briois, Sandrine, Cornic, Mathias, Elisee, Virginie, Denis, Jesuthasan, Djadi-Prat, Juliette, Jouany, Pauline, Junquera, Ramon, Henriques, Mickael, Kebir, Amina, Lehir, Isabelle, Meunier, Jeanne, Patin, Florence, Paquet, Val.rie, Tréhan, Anne, Vigna, Véronique, Sabatier, Brigitte, Bergerot, Damien, Jouve, Charléne, Knosp, Camille, Lenoir, Olivia, Mahtal, Nassim, Resmini, Léa, Lescure, Xavier, Ghosn, Jade, Bachelard, Antoine, Rachline, Anne, Isernia, Valentina, Bao-chau, Phung, Vallois, Dorothée, Sautereau, Aurelie, Neukrich, Catherine, Dossier, Antoine, Borie, Raphaël, Crestani, Bruno, Ducrocq, Gregory, Steg, Philippe Gabriel, Dieude, Philippe, Papo, Thomas, Marcault, Estelle, Chaudhry, Marhaba, Da Silveira, Charléne, Metois, Annabelle, Mahenni, Ismahan, Meziani, Meriam, Nilusmas, Cyndie, Le Gac, Sylvie, Ndiaye, Awa, Louni, Fran.oise, Chansombat, Malikhone, Julia, Zelie, Chalal, Solaya, Chalal, Lynda, Kramer, Laura, Le Grand, Jeniffer, Ouifiya, Kafif, Piquard, Valentine, Tubiana, Sarah, Nguyen, Yann, Honsel, Vasco, Weiss, Emmanuel, Codorniu, Anais, Zarrouk, Virginie, de Lastours, Victoire, Uzzan, Matthieu, Gamany, Naura, Claveirole, Agathe, Navid, Alexandre, Fouque, Tiffanie, Cohen, Yonathan, Lupo, Maya, Gilles, Constance, Rahli, Roza, Louis, Zeina, Boutboul, David, Galicier, Lionel, Amara, Yaël, Archer, Gabrielle, Benattia, Amira, Bergeron, Anne, Bondeelle, Louise, de Castro, Nathalie, Clément, Melissa, Darmon, Michaël, Denis, Blandine, Dupin, Clairelyne, Feredj, Elsa, Feyeux, Delphine, Joseph, Adrien, Lenglin, Etienne, Le Guen, Pierre, Liégeon, Geoffroy, Lorillon, Gwenaël, Mabrouki, Asma, Mariotte, Eric, Martin de Frémont, Grégoire, Mirouse, Adrien, Molina, Jean-Michel, Peffault de Latour, Régis, Oksenhendler, Eric, Saussereau, Julien, Tazi, Abdellatif, Tudesq, Jean-Jacques, Zafrani, Lara, Brindele, Isabelle, Bugnet, Emmanuelle, Lebras, Karine Celli, Chabert, Julien, Djaghout, Lamia, Fauvaux, Catherine, Jegu, Anne Lise, Kozakiewicz, Ewa, Meunier, Martine, Tremorin, Marie-Thérèse, Davoine, Claire, Madelaine, Isabelle, Caillat-Zucman, Sophie, Delaugerre, Constance, Morin, Florence, Sène, Damien, Burlacu, Ruxandra, Chousterman, Benjamin, Mégarbanne, Bruno, Richette, Pascal, Riveline, Jean-Pierre, Frazier, Aline, Vicaut, Eric, Berton, Laure, Hadjam, Tassadit, Vazquez-Ibarra, Miguel Alejandro, Jourdaine, Clément, Tran, Olivia, Jouis, Véronique, Jacob, Aude, Smati, Julie, Renaud, Stéphane, Pernin, Claire, Suarez, Lydia, Semerano, Luca, Abad, Sébastien, nainous, Ruben B., Bonnet, Nicolas, Comparon, Celine, Cohen, Yves, Cordel, Hugues, Dhote, Robin, Dournon, Nathalie, Duchemann, Boris, Ebstein, Nathan, Gille, Thomas, Giroux-Leprieur, Benedicte, Goupil de Bouille, Jeanne, Nunes, Hilario, Oziel, Johanna, Roulot, Dominique, Sese, Lucile, ClaireTantet, Uzunhan, Yurdagul, Bloch-Queyrat, Coralie, Levy, Vincent, Messani, Fadhila, Rahaoui, Mohammed, Petit, Myléne, Brahmi, Sabrina, Rathoin, Vanessa, Rigal, Marthe, Costedoat-Chalumeau, Nathalie, Luong, Liem Binh, Hamou, Zakaria Ait, Benghanem, Sarah, Blanche, Philippe, Carlier, Nicolas, Chaigne, Benjamin, Gauzit, Remy, Joumaa, Hassan, Jozwiak, Mathieu, Lachétre, Marie, Lafoeste, Hélène, Launay, Odie, Legendre, Paul, Marey, Jonathan, Morbieu, Caroline, Palmieri, Lola-Jade, Szwebel, Tali-Anne, Abdoul, Hendy, Bruneau, Alexandra, Beclin-Clabaux, Audrey, Larrieu, Charly, Montanari, Pierre, Dufour, Eric, Clarke, Ada, Le Bourlout, Catherine, Marin, Nathalie, Menage, Nathalie, Saleh-Mghir, Samira, Cisse, Mamadou Salif, Cheref, Kahina, Guerin, Corinne, Zerbit, Jérémie, Michel, Marc, Gallien, Sébastien, Crickx, Etienne, Le Vavasseur, Benjamin, Kempf, Emmanuelle, Jaffal, Karim, Vindrios, William, Oniszczuk, Julie, Guillaud, Constance, Lim, Pascal, Fois, Elena, Melica, Giovanna, Matignon, Marie, Jalabert, Maud, Lelièvre, Jean-Daniel, Schmitz, David, Bourhis, Marion, Belazouz, Sylia, Languille, Laetitia, Boucle, Caroline, Cita, Nelly, Didier, Agnés, Froura, Fahem, Ledudal, Katia, Sadaoui, Thiziri, Thiemele, Alaki, Le Febvre De Bailly, Delphine, Verlinde, Muriel Carvhalo, Mayaux, Julien, Cacoub, Patrice, Saadoun, David, Vautier, Mathieu, Bugaut, Héléne, Benveniste, Olivier, Allenbach, Yves, Leroux, Gaëlle, Rigolet, Aude, Guillaume-Jugnot, Perrine, Domont, Fanny, Desbois, Anne Claire, Comarmond, Chloé, Champtiaux, Nicolas, Toquet, Segolene, Ghembaza, Amine, Vieira, Matheus, Maalouf, Georgina, Boleto, Goncalo, Ferfar, Yasmina, Corvol, Jean-Christophe, Louapre, C.line, Sambin, Sara, Mariani, Louise-Laure, Karachi, Carine, Tubach, Florence, Estellat, Candice, Gimeno, Linda, Martin, Karine, Bah, Aicha, Keo, Vixra, Ouamri, Sabrine, Messaoudi, Yasmine, Yelles, Nessima, Faye, Pierre, Cavelot, Sebastien, Larcheveque, Cecile, Annonay, Laurence, Benhida, Jaouad, Zahrate-Ghoul, Aida, Hammal, Soumeya, Belilita, Ridha, Charbonnier, Fanny, Aguilar, Claire, Alby-Laurent, Fanny, Burger, Carole, Campos-Vega, Clara, Chavarot, Nathalie, Fournier, Benjamin, Rouzaud, Claire, Vimpére, Damien, Elie, Caroline, Bakouboula, Prissile, Choupeaux, Laure, Granville, Sophie, Issorat, Elodie, Broissand, Christine, Alyanakian, Marie-Alexandra, Geri, Guillaume, Derridj, Nawal, Sguiouar, Naima, Meddah, Hakim, Djadel, Mourad, Chambrin-Lauvray, Héléne, Duclos-vallée, Jean-Charles, Saliba, Faouzi, Sacleux, Sophie-Caroline, Kounis, Ilias, Tamazirt, Sonia, Rudant, Eric, Michot, Jean-Marie, Stoclin, Annabelle, Colomba, Emeline, Pommeret, Fanny, Willekens, Christophe, Da Silva, Rosa, Dejean, Valérie, Mekid, Yasmina, Ben-Mabrouk, Ines, Netzer, Florence, Pradon, Caroline, Drouard, Laurence, Camara-Clayette, Valérie, Morel, Alexandre, Garcia, Gilles, Mohebbi, Abolfazl, Berbour, Férial, Dehais, Mélanie, Pouliquen, Anne-Lise, Klasen, Alison, Soyez-Herkert, Loren, London, Jonathan, Keroumi, Younes, Guillot, Emmanuelle, Grailles, Guillaume, El amine, Younes, Defrancq, Fanny, Fodil, Hanane, Bouras, Chaouki, Dautel, Dominique, Gambier, Nicolas, Dieye, Thierno, Bienvenu, Boris, Lancon, Victor, Lecomte, Laurence, Beziriganyan, Kristina, Asselate, Belkacem, Allanic, Laure, Kiouris, Elena, Legros, Marie-Héléne, Lemagner, Christine, Martel, Pascal, Provitolo, Vincent, Ackermann, Félix, Le Marchand, Mathilde, Chan Hew Wai, Aurélie, Fremont, Dimitri, Coupez, Elisabeth, Adda, Mireille, Duée, Frédéric, Bernard, Lise, Gros, Antoine, Henry, Estelle, Courtin, Claire, Pattyn, Anne, Guinot, Pierre-Grégoire, Bardou, Marc, Maurer, Agnes, Jambon, Julie, Cransac, Amélie, Pernot, Corinne, Mourvillier, Bruno, Marquis, Eric, Benoit, Philippe, Roux, Damien, Gernez, Coralie, Yelnik, Cécile, Poissy, Julien, Nizard, Mandy, Denies, Fanette, Gros, Helene, Mourad, Jean-Jacques, Sacco, Emmanuelle, Renet, Sophie, Ader, F., Yazdanpanah, Y., Mentre, F., Peiffer-Smadja, N., Lescure, F.X., Poissy, J., Bouadma, L., Timsit, J.F., Lina, B., Morfin-Sherpa, F., Bouscambert, M., Gaymard, A., Peytavin, G., Abel, L., Guedj, J., Andrejak, C., Burdet, C., Laouenan, C., Belhadi, D., Dupont, A., Alfaiate, T., Basli, B., Chair, A., Laribi, S., Level, J., Schneider, M., Tellier, M.C., Dechanet, A., Costagliola, D., Terrier, B., Ohana, M., Couffin-Cadiergues, S., Esperou, H., Delmas, C., Saillard, J., Fougerou, C., Moinot, L., Wittkop, L., Cagnot, C., Le Mestre, S., Lebrasseur-Longuet, D., Petrov-Sanchez, V., Diallo, A., Mercier, N., Icard, V., Leveau, B., Tubiana, S., Hamze, B., Gelley, A., Noret, M., D’Ortenzio, E., Puechal, O., Semaille, C., Welte, T., Paiva, J.A., Halanova, M., Kieny, M.P., Balssa, E., Birkle, C., Gibowski, S., Landry, E., Le Goff, A., Moachon, L., Moins, C., Wadouachi, L., Paul, C., Levier, A., Bougon, D., Djossou, F., Epelboin, L., Dellamonica, J., Marquette, C.H., Robert, C., Gibot, S., Senneville, E., Jean-Michel, V., Zerbib, Y., Chirouze, C., Boyer, A., Cazanave, C., Gruson, D., Malvy, D., Andreu, P., Quenot, J.P., Terzi, N., Faure, K., Chabartier, C., Le Moing, V., Klouche, K., Ferry, T., F, Valour, Gaborit, B., Canet, E., Le Turnier, P., Boutoille, D., Bani-Sadr, F., Benezit, F., Revest, M., Cameli, C., Caro, A., Um Tegue, MJ Ngo, Le Tulzo, Y., Laviolle, B., Laine, F., Thiery, G., Meziani, F., Hansmann, Y., Oulehri, W., Tacquard, C., Vardon-Bounes, F., Riu-Poulenc, B., Murris-Espin, M., Bernard, L., Garot, D., Hinschberger, O., Martinot, M., Bruel, C., Pilmis, B., Bouchaud, O., Loubet, P., Roger, C., Monnet, X., Figueiredo, S., Godard, V., Mira, J.P., Lachatre, M., Kerneis, S., Aboab, J., Sayre, N., Crockett, F., Lebeaux, D., Buffet, A., Diehl, J.L., Fayol, A., Hulot, J.S., Livrozet, M., Dessap, A Mekontso, Ficko, C., Stefan, F., Le Pavec, J., Mayaux, J., Ait-Oufella, H., Molina, J.M., Pialoux, G., Fartoukh, M., Textoris, J., Brossard, M., Essat, A., Netzer, E., Riault, Y., Ghislain, M., Beniguel, L., Genin, M., Gouichiche, L., Betard, C., Belkhir, L., Altdorfer, A., Centro, V Fraipont, Braz, S., Ribeiro, JM Ferreira, Alburqueque, R Roncon, Berna, M., Alexandre, M., Lamprecht, B., Egle, A., Greil, R., Joannidis, M., Patterson, Thomas F., Ponce, Philip O., Taylor, Barbara S., Patterson, Jan E., Bowling, Jason E., Javeri, Heta, Kalil, Andre C., Larson, LuAnn, Hewlett, Angela, Mehta, Aneesh K., Rouphael, Nadine G., Saklawi, Youssef, Scanlon, Nicholas, Traenkner, Jessica J., Trible, Ronald P., Jr., Walter, Emmanuel B., Ivey, Noel, Holland, Thomas L., Ruiz-Palacios, Guillermo M., Ponce de León, Alfredo, Rajme, Sandra, Hsieh, Lanny, Amin, Alpesh N., Watanabe, Miki, Lee, Helen S., Kline, Susan, Billings, Joanne, Noren, Brooke, Kim, Hyun, Bold, Tyler D., Tapson, Victor, Grein, Jonathan, Sutterwala, Fayyaz, Iovine, Nicole, Beattie, Lars K., Wakeman, Rebecca Murray, Shaw, Matthew, Jain, Mamta K., Mocherla, Satish, Meisner, Jessica, Luque, Amneris, Sweeney, Daniel A., Benson, Constance A., Ali, Farhana, Atmar, Robert L., El Sahly, Hana M., Whitaker, Jennifer, Falsey, Ann R., Branche, Angela R., Rozario, Cheryl, Pineda, Justino Regalado, Martinez-Orozco, José Arturo, Lye, David Chien, Ong, Sean WX., Chia, Po Ying, Young, Barnaby E., Sandkovsky, Uriel, Berhe, Mezgebe, Haley, Clinton, Dishner, Emma, Cantos, Valeria D., Kelley, Colleen F., Rebolledo Esteinou, Paulina A., Kandiah, Sheetal, Doernberg, Sarah B., Crouch, Pierre-Cedric B., Jang, Hannah, Luetkemeyer, Anne F., Dwyer, Jay, Cohen, Stuart H., Thompson, George R., 3rd, Nguyen, Hien H., Finberg, Robert W., Wang, Jennifer P., Perez-Velazquez, Juan, Wessolossky, Mireya, Jackson, Patrick E.H., Bell, Taison D., West, Miranda J., Taiwo, Babafemi, Krueger, Karen, Perez, Johnny, Pearson, Triniece, Paules, Catharine I., Julian, Kathleen G., Ahmad, Danish, Hajduczok, Alexander G., Arguinchona, Henry, Arguinchona, Christa, Erdmann, Nathaniel, Goepfert, Paul, Ahuja, Neera, Frank, Maria G., Wyles, David, Young, Heather, Oh, Myoung-don, Park, Wan Beom, Kang, Chang Kyung, Marconi, Vincent, Moanna, Abeer, Cribbs, Sushma, Harrison, Telisha, Kim, Eu Suk, Jung, Jongtak, Song, Kyoung-Ho, Kim, Hong Bin, Tan, Seow Yen, Shafi, Humaira, Chien, Jaime, Fong, Raymond KC., Murray, Daniel D., Lundgren, Jens, Nielsen, Henrik, Jensen, Tomas, Zingman, Barry S., Grossberg, Robert, Riska, Paul F., Yang, Otto O., Ahn, Jenny, Arias, Rubi, Rapaka, Rekha R., Hauser, Naomi, Campbell, James D., Short, William R., Tebas, Pablo, Baron, Jillian T., McLellan, Susan L.F., Blanton, Lucas S., Seashore, Justin B., Creech, C. Buddy, Rice, Todd W., Walker, Shannon, Thomsen, Isaac P., Lopez de Castilla, Diego, Van Winkle, Jason W., Riedo, Francis X., Pada, Surinder Kaur, Wang, Alvin DY., Lin, Li, Harkins, Michelle, Mertz, Gregory, Sosa, Nestor, Ann Chai, Louis Yi, Tambyah, Paul Anantharajah, Tham, Sai Meng, Archuleta, Sophia, Yan, Gabriel, Lindholm, David A., Markelz, Ana Elizabeth, Mende, Katrin, Mularski, Richard, Hohmann, Elizabeth, Torres-Soto, Mariam, Jilg, Nikolaus, Maves, Ryan C., Utz, Gregory C., George, Sarah L., Hoft, Daniel F., Brien, James D., Paredes, Roger, Mateu, Lourdes, Loste, Cora, Kumar, Princy, Thornton, Sarah, Mohanraj, Sharmila, Hynes, Noreen A., Sauer, Lauren M., Colombo, Christopher J., Schofield, Christina, Colombo, Rhonda E., Chambers, Susan E., Novak, Richard M., Wendrow, Andrea, Gupta, Samir K., Lee, Tida, Lalani, Tahaniyat, Holodniy, Mark, Chary, Aarthi, Huprikar, Nikhil, Ganesan, Anuradha, Ohmagari, Norio, Mikami, Ayako, Price, D. Ashley, Duncan, Christopher J.A., Dierberg, Kerry, Neumann, Henry J., Taylor, Stephanie N., Lacour, Alisha, Masri, Najy, Swiatlo, Edwin, Widmer, Kyle, Neaton, James D., Bessesen, Mary, Stephens, David S., Burgess, Timothy H., Uyeki, Timothy M., Walker, Robert, Marks, G. Lynn, Osinusi, Anu, Cao, Huyen, Cardoso, Anabela, de Bono, Stephanie, Schlichting, Douglas E., Chung, Kevin K., Ferreira, Jennifer L., Green, Michelle, Makowski, Mat, Wierzbicki, Michael R., Conrad, Tom M., El-Khorazaty, Jill Ann, Hill, Heather, Bonnett, Tyler, Gettinger, Nikki, Engel, Theresa, Lewis, Teri, Wang, Jing, Beigel, John H., Tomashek, Kay M., Ghazaryan, Varduhi, Beresnev, Tatiana, Nayak, Seema, Dodd, Lori E., Dempsey, Walla, Nomicos, Effie, Lee, Marina, Pikaart-Tautges, Rhonda, Elsafy, Mohamed, Jurao, Robert, Koo, Hyung, Proschan, Michael, Yokum, Tammy, Arega, Janice, Florese, Ruth, Voell, Jocelyn D., Davey, Richard, Serrano, Ruth C., Wiley, Zanthia, Phadke, Varun K., Goepfert, Paul A., Gomez, Carlos A., Sofarelli, Theresa A., Certain, Laura, Imlay, Hannah N., Wolfe, Cameron R., Ko, Emily R., Engemann, John J., Felix, Nora Bautista, Wan, Claire R., Elmor, Sammy T., Bristow, Laurel R., Harkins, Michelle S., Iovine, Nicole M., Elie-Turenne, Marie-Carmelle, Tapson, Victor F., Choe, Pyoeng Gyun, Mularski, Richard A., Rhie, Kevin S., Hussein, Rezhan H., Ince, Dilek, Winokur, Patricia L., Takasaki, Jin, Saito, Sho, McConnell, Kimberly, Wyles, David L., Sarcone, Ellen, Grimes, Kevin A., Perez, Katherine, Janak, Charles, Whitaker, Jennifer A., Rebolledo, Paulina A., Gharbin, John, Lambert, Allison A., Zea, Diego F., Bainbridge, Emma, Hostler, David C., Hostler, Jordanna M., Shahan, Brian T., Ling, Evelyn, Go, Minjoung, Hubbard, Fleesie A., Chakrabarty, Melony, Laguio-Vila, Maryrose, Walsh, Edward E., Guirgis, Faheem, Marconi, Vincent C., Madar, Christian, Borgetti, Scott A., Levine, Corri, Nock, Joy, Candiotti, Keith, Rozman, Julia, Dangond, Fernando, Hyvert, Yann, Seitzinger, Andrea, Cross, Kaitlyn, Pettibone, Stephanie, Nayak, Seema U., Deye, Gregory A., Siempos, Ilias I., Belhadi, Drifa, Veiga, Viviane Cordeiro, Cavalcanti, Alexandre Biasi, Branch-Elliman, Westyn, Papoutsi, Eleni, Gkirgkiris, Konstantinos, Xixi, Nikoleta A., and Kotanidou, Anastasia

Published
2024
Full Text
View/download PDF

4. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Author

Albiges, Laurence, Foulon, Stéphanie, Bayle, Arnaud, Gachot, Bertrand, Pommeret, Fanny, Willekens, Christophe, Stoclin, Annabelle, Merad, Mansouria, Griscelli, Frank, Lacroix, Ludovic, Netzer, Florence, Hueso, Thomas, Balleyguier, Corinne, Ammari, Samy, Colomba, Emeline, Baciarello, Giulia, Perret, Audrey, Hollebecque, Antoine, Hadoux, Julien, Michot, Jean-Marie, Chaput, Nathalie, Saada, Veronique, Hauchecorne, Mathilde, Micol, Jean-Baptiste, Sun, Roger, Valteau-Couanet, Dominique, André, Fabrice, Scotte, Florian, Besse, Benjamin, Soria, Jean-Charles, and Barlesi, Fabrice

Published
2020
Full Text
View/download PDF

5. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

Author

Lucas, Nolwenn, Duchmann, Matthieu, Rameau, Philippe, Noël, Floriane, Michea, Paula, Saada, Véronique, Kosmider, Olivier, Pierron, Gérard, Fernandez-Zapico, Martin E, Howard, Matthew T., King, Rebecca L., Niyongere, Sandrine, Diop, M’boyba Khadija, Fenaux, Pierre, Itzykson, Raphael, Willekens, Christophe, Ribrag, Vincent, Fontenay, Michaela, Padron, Eric, Soumelis, Vassili, Droin, Nathalie, Patnaik, Mrinal M, and Solary, Eric

Published
2019
Full Text
View/download PDF

6. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Author

Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, and Kroemer, Guido

Published
2021
Full Text
View/download PDF

7. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Author

Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, and Tallman, Martin S.

Published
2017
Full Text
View/download PDF

8. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

Author

Willekens, Christophe, Renneville, Aline, Broutin, Sophie, Saada, Véronique, Micol, Jean-Baptiste, Delahousse, Julia, Poinsignon, Vianney, Bories, Claire, Berthon, Céline, Itzykson, Raphael, Boissel, Nicolas, Quivoron, Cyril, Terroir-Cassou-Mounat, Marie, Bosq, Jacques, Preudhomme, Claude, Paci, Angelo, Penard-Lacronique, Virginie, and De Botton, Stéphane

Published
2018
Full Text
View/download PDF

9. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Author

Quek, Lynn, David, Muriel D., Kennedy, Alison, Metzner, Marlen, Amatangelo, Michael, Shih, Alan, Stoilova, Bilyana, Quivoron, Cyril, Heiblig, Maël, Willekens, Christophe, Saada, Véronique, Alsafadi, Samar, Vijayabaskar, M. S., Peniket, Andy, Bernard, Oliver A., Agresta, Sam, Yen, Katharine, MacBeth, Kyle, Stein, Eytan, Vassiliou, George S., Levine, Ross, De Botton, Stephane, Thakurta, Anjan, Penard-Lacronique, Virginie, and Vyas, Paresh

Published
2018
Full Text
View/download PDF

10. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.

Author

Willekens, Christophe, Chahine, Claude, Dragani, Matteo, Khalife‐Hachem, Sabine, Bigenwald, Camille, Rossignol, Julien, Castilla‐Llorente, Cristina, Danu, Alina, Michot, Jean‐Marie, Saada, Veronique, Cotteret, Sophie, Marzac, Christophe, Renneville, Aline, Plo, Isabelle, Broutin, Sophie, Bosselut, Nelly, Cassinat, Bruno, Lazarovici, Julien, Droin, Nathalie, and De Botton, Stephane

Published
2023
Full Text
View/download PDF

11. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Author

Selimoglu-Buet, Dorothée, Wagner-Ballon, Orianne, Saada, Véronique, Bardet, Valérie, Itzykson, Raphaël, Bencheikh, Laura, Morabito, Margot, Met, Elisabeth, Debord, Camille, Benayoun, Emmanuel, Nloga, Anne-Marie, Fenaux, Pierre, Braun, Thorsten, Willekens, Christophe, Quesnel, Bruno, Adès, Lionel, Fontenay, Michaela, Rameau, Philippe, Droin, Nathalie, Koscielny, Serge, and Solary, Eric

Published
2015
Full Text
View/download PDF

15. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.

Author

Bigenwald, Camille, Haddad, Yacine, Thelemaque, Cassandra, Carrier, Agathe, Birebent, Roxanne, Ly, Pierre, Flament, Caroline, Lahmar, Imran, de Sousa, Eric, Maeurer, Markus, Miyara, Makoto, Assi, Tarek, Castilla-Llorente, Cristina, Willekens, Christophe, Fayemi, Céline, Lazarovici, Julien, Marabelle, Aurélien, Derosa, Lisa, Ribrag, Vincent, and Zitvogel, Laurence

Subjects
MEDICAL personnel, HEMATOLOGIC malignancies, COVID-19 pandemic, SARS-CoV-2, MULTIPLE myeloma
Abstract

The SARS-CoV-2 pandemic still represents a threat for immunosuppressed and hematological malignancy (HM) bearing patients, causing increased morbidity and mortality. Given the low anti-SARSCoV-2 IgG titers post-vaccination, the COVID-19 threat prompted the prophylactic use of engineered anti-SARS-CoV-2 monoclonal antibodies. In addition, potential clinical significance of T cell responses has been overlooked during the first waves of the pandemic, calling for additional in-depth studies. We reported that the polarity and the repertoire of T cell immune responses govern the susceptibility to SARS-CoV-2 infection in health care workers and solid cancer patients. Here, we longitudinally analyzed humoral and cellular immune responses at each BNT162b2 mRNA vaccine injection in 47 HM patients under therapy. Only one-third of HM, mostly multiple myeloma (MM) bearing patients, could mount S1-RBD-specific IgG responses following BNT162b2 mRNA vaccines. This vaccine elicited a S1-RBD-specific Th1 immune response in about 20% patients, mostly in MM and Hodgkin lymphoma, while exacerbating Th2 responses in the 10% cases that presented this recognition pattern at baseline (mostly rituximab-treated patients). Performing a third booster barely improved the percentage of patients developing an S1-RBD-specific Th1 immunity and failed to seroconvert additional HM patients. Finally, 16 patients were infected with SARS-CoV-2, of whom 6 developed a severe infection. Only S1-RBD-specific Th1 responses were associated with protection against SARS-CoV2 infection, while Th2 responses or anti-S1-RBD IgG titers failed to correlate with protection. These findings herald the paramount relevance of vaccine-induced Th1 immune responses in hematological malignancies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Author

Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio Segura, Cecilia del Carmen, Molinero, César, Mascaró, Cristina, Vila, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch José, Francesc Xavier, The University of Manchester, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Salamero O, Carpio C, Bosch F] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Montesinos P] Hospital Universitari I Politécnic La Fe, València, Spain. Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain. [Willekens C] Institut Gustave Roussy, Villejuif Cedex, France. [Pérez-Simón JA] Hospital Universitario Virgen del Rocío, Sevilla, Spain. Instituto de Biomedicina de Sevilla (Insitituto de Biomedicina De Sevilla/Consejo Superior De Investigaciones Científicas/Centro de Investigación Biomédica en Red de Cáncer), Universidad de Sevilla, Sevilla, Spain. [Pigneux A] Centre Hospitalier Universitaire CHU Bordeaux, Hôpital du Haut Lévêque, Pessac, France. [Récher C] Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France, Vall d'Hebron Barcelona Hospital Campus, Ministerio de Economía y Competitividad (España), European Commission, Cancer Research UK, Centro para el Desarrollo Tecnológico Industrial (España), National Institute for Health Research (UK), University College London, and NIHR Biomedical Research Centre (UK)

Subjects
Adult, Male, Cancer Research, Myeloid, Lysine-Specific Histone Demethylase 1A, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos [COMPUESTOS QUÍMICOS Y DROGAS], neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES], Refractory, In vivo, Recurrence, hemic and lymphatic diseases, medicine, Hematologic Malignancy, Humans, Other subheadings::/therapeutic use [Other subheadings], Enzyme Inhibitors, Aged, Aged, 80 and over, Histone Demethylases, business.industry, Leucèmia mieloide aguda, Otros calificadores::/uso terapéutico [Otros calificadores], Myeloid leukemia, Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [DISEASES], KDM1A, ORIGINAL REPORTS, Middle Aged, medicine.disease, In vitro, Leukemia, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Oncology, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors [CHEMICALS AND DRUGS], Cancer research, Female, business, Inhibidors enzimàtics - Ús terapèutic
Abstract

[Purpose] Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML)., [Methods] This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor., [Results] Twenty-seven patients were treated with iadademstat on days 1 to 5 (5-220 µg/m2/d) of each week in 28-day cycles in a DE phase that resulted in a recommended dose of 140 µg/m2/d of iadademstat as a single agent. This dose was chosen to treat all patients (n = 14) in an EC enriched with patients with MLL/KMT2A-rearranged AML. Most adverse events (AEs) were as expected in R/R AML and included myelosuppression and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea. PK data demonstrated a dose-dependent increase in plasma exposure, and PD data confirmed a potent time- and exposure-dependent induction of differentiation biomarkers. Reductions in blood and bone marrow blast percentages were observed, together with induction of blast cell differentiation, in particular, in patients with MLL translocations. One complete remission with incomplete count recovery was observed in the DE arm., [Conclusion] Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing (EudraCT No.: 2018-000482-36)., Supported by Oryzon Genomics and IPT-2012-0673-010000 of the INNPACTO program of the Spanish Ministry of Economy and Competitiveness, with contribution of Fondo Europeo de Desarrollo Regional (FEDER) from the European Union and CDTI_CIIP-20131005/EUROSTAR_E18159. T.C.P.S. is supported by Cancer Research UK Grant No. C5759/A20971. R.P. is supported by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre.

Published
2020

19. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening

Author

Hueso, Thomas, Ekpe, Kenneth, Mayeur, Camille, Gatse, Anna, Joncquel-Chevallier Curt, Marie, Gricourt, Guillaume, Rodriguez, Christophe, Burdet, Charles, Ulmann, Guillaume, Neut, Christel, Amini, Salah-Eddine, Lepage, Patricia, Raynard, Bruno, Willekens, Christophe, Micol, Jean-Baptiste, de Botton, Stéphane, Yakoub-Agha, Ibrahim, Gottrand, Frédéric, Desseyn, Jean-Luc, Thomas, Muriel, Woerther, Paul-Louis, Seguy, David, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire de Lille (CHU Lille), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Emergence de la résistance bactérienne in vivo (EA3964), Université Paris Diderot - Paris 7 (UPD7), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Institut Gustave Roussy (IGR), Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Centre hospitalier universitaire Henri-Mondor [Créteil], Dynamic Microbiology - EA 7380 (DYNAMIC), École nationale vétérinaire - Alfort (ENVA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est (UPE)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University Hospital of Lille, MSD, École nationale vétérinaire d'Alfort (ENVA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Lille, and Tâche, Roselyne

Subjects
Adult, Male, [SDV]Life Sciences [q-bio], Mice, Transgenic, chemotherapy, Feces, Mice, mucus, Antineoplastic Combined Chemotherapy Protocols, microbiota, Animals, Humans, acute leukemia, Intestinal Mucosa, lcsh:RC799-869, Aged, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Induction Chemotherapy, Middle Aged, Fatty Acids, Volatile, Gastrointestinal Microbiome, [SDV] Life Sciences [q-bio], Leukemia, Myeloid, Acute, intestinal barrier, Dysbiosis, Female, lcsh:Diseases of the digestive system. Gastroenterology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Article, Research Paper
Abstract

International audience; Induction chemotherapy (7 + 3 regimen) remains the gold standard for patients with acute myeloid leukemia (AML) but is responsible for gut damage leading to several complications such as bloodstream infection (BSI). We aimed to investigate the impact of induction chemotherapy on the intestinal barrier of patients with AML and in wild-type mice. Next, we assessed the potential benefit of strengthening the mucosal barrier in transgenic mice releasing a recombinant protein able to reinforce the mucus layer (Tg222). In patients, we observed a decrease of plasma citrulline, which is a marker of the functional enterocyte mass, of short-chain fatty acids and of fecal bacterial load, except forEscherichia coliandEnterococcusspp., which became dominant. Both the alpha and beta-diversities of fecal microbiota decreased. In wild-type mice, citrulline levels decreased under chemotherapy along with an increase ofE. coliandEnterococcusspp load associated with concomitant histologic impairment. By comparison with wild-type mice, Tg222 mice, 3 days after completing chemotherapy, had higher citrulline levels, a faster healing epithelium, and preserved alpha-diversity of their intestinal microbiota. This was associated with reduced bacterial translocations. Our results highlight the intestinal damage and the dysbiosis induced by the 7 + 3 regimen. As a proof of concept, our transgenic model suggests that strengthening the intestinal barrier is a promising approach to limit BSI and improve AML patients' outcome.

Published
2020

23. Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Author

Willekens, Christophe, Chraibi, Samy, Decroocq, Justine, Carpentier, Benjamin, Lebon, Delphine, Bonnet, Sarah, Gauthier, Nicolas, Pagès, Arnaud, Dragani, Matteo, Khalife-Hachem, Sabine, Micol, Jean-Baptiste, Pasquier, Florence, Wickenhauser, Stefan, Saada, Véronique, Vergé, Véronique, Arbab, Ahmadreza, Marzac, Christophe, Pascal, Laurent, Roos-Weil, Damien, Jourdan, Eric, Bouscary, Didier, and de Botton, Stéphane

Published
2022
Full Text
View/download PDF

24. A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset

Author

Selimoglu-Buet, Dorothée, Rivière, Julie, Ghamlouch, Hussein, Bencheikh, Laura, Lacout, Catherine, Morabito, Margot, Diop, M’boyba, Meurice, Guillaume, Breckler, Marie, Chauveau, Aurélie, Debord, Camille, Debeurme, Franck, Itzykson, Raphael, Chapuis, Nicolas, Willekens, Christophe, Wagner-Ballon, Orianne, Bernard, Olivier A., Droin, Nathalie, Solary, Eric, Hématopoïèse normale et pathologique (U1170 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Plateforme de Bioinformatique [Gustave Roussy], Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etude du Polymorphisme des Génomes Végétaux (EPGV), Institut National de la Recherche Agronomique (INRA), Service d'Hématologie Biologique [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Hématopoïèse normale et pathologique, Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Direction des systèmes d'information, Ministére des Affaires Etrangères, Ministère de l'Europe et des Affaires étrangères (MEAE), Service d'Hématologie Clinique [CHU Lille], Hôpital Claude Huriez, CHU Henri Mondor, Université Paris-Sud 11 - Faculté de médecine (UP11 UFR Médecine), Centre de Recherches Juridiques de l'Université de Franche-Comté - UFC (EA 3225) (CRJFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC), Département d'hématologie [Gustave Roussy], and Institut Gustave Roussy (IGR)

Subjects
Male, Mice, Knockout, Gene Expression Regulation, Leukemic, Science, Primary Cell Culture, Down-Regulation, Leukemia, Myelomonocytic, Chronic, [SDV.CAN]Life Sciences [q-bio]/Cancer, DNA Methylation, Article, Monocytes, Dioxygenases, DNA-Binding Proteins, Mice, MicroRNAs, Proto-Oncogene Proteins, Animals, Humans, Female, lcsh:Q, K562 Cells, Promoter Regions, Genetic, lcsh:Science
Abstract

Non-classical monocyte subsets may derive from classical monocyte differentiation and the proportion of each subset is tightly controlled. Deregulation of this repartition is observed in diverse human diseases, including chronic myelomonocytic leukemia (CMML) in which non-classical monocyte numbers are significantly decreased relative to healthy controls. Here, we identify a down-regulation of hsa-miR-150 through methylation of a lineage-specific promoter in CMML monocytes. Mir150 knock-out mice demonstrate a cell-autonomous defect in non-classical monocytes. Our pulldown experiments point to Ten-Eleven-Translocation-3 (TET3) mRNA as a hsa-miR-150 target in classical human monocytes. We show that Tet3 knockout mice generate an increased number of non-classical monocytes. Our results identify the miR-150/TET3 axis as being involved in the generation of non-classical monocytes., A decrease in the fraction of non-classical monocytes is a hallmark of chronic myelomonocytic leukaemia. Taking advantage of this abnormal situation, the authors identify a mechanistic link between miR-150 and TET3 as being involved in monocyte subset generation.

Published
2018

25. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.

Author

Corfmat, Marion, Willekens, Christophe, Vinit, Julien, Bussone, Guillaume, Fenaux, Pierre, Fain, Olivier, Klatzmann, David, Mekinian, Arsene, Comont, Thibault, and malignancies), MINHEMON (French network of dysimmune disorders associated to hematological

Subjects
*STEROID drugs, *MYELODYSPLASTIC syndromes, *DISEASE progression, *INTERLEUKIN-2, *SYSTEMIC inflammatory response syndrome, *TREATMENT effectiveness, *IMMUNOLOGIC diseases, *T cells, *DRUG side effects, *DISEASE complications, *SYMPTOMS, *EVALUATION
Abstract

Objectives Systemic inflammatory and autoimmune diseases can be associated with myelodysplastic syndromes. Current treatments (steroids, immunosuppressive agents, biologics) are unsatisfactory because of their low response rate, dependence or adverse events. We aimed at evaluating the effects of low doses of IL-2 (ld-IL2) as a regulatory T-cell inducer in this context. Methods We treated three patients with ld-IL2 with myelodysplastic syndromes and an associated dysimmune disorder (polymyalgia rheumatic, relapsing polychondritis associated with Sweet's syndrome and vasculitis with cutaneous and joint involvement, respectively). All three patients were dependent on steroids and refractory to biologics or azacitidine. They received doses of 1–1.5 million units of proleukin/day during 5 days and then every fortnight. Results The treatment led to a clinical improvement and steroid sparing in 2/3 patients with no serious adverse events, and no progression of the disease. Conclusion Our results support the investigation of ld-IL2 in MDS associated with immune disorders in controlled clinical studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies.

Author

Pegliasco, Jean, Schmaltz-Panneau, Barbara, Martin, Jean-Edouard, Chraibi, Samy, Khalife-Hachem, Sabine, Salviat, Flore, Pasquier, Florence, Willekens, Christophe, Lopez, Maureen, Ben-ali, Adel, Bera, Odile, Caron, Olivier, Castilla-Llorent, Cristina, Cotteret, Sophie, Bourdin, Carole, Saada, Veronique, Auger, Nathalie, de Botton, Stephane, Vainchenker, William, and Fuseau, Pascal

Subjects
ACUTE myeloid leukemia, GERM cells
Abstract

Germline mutations in adult AML patients are uncommon and often associated with organ dysfunction (i.e. I GATA2 i deficiency [[6]]) or a preexisting hematologic disorders (i.e. thrombocytopenia in I RUNX1 i mutated patients [[7]]), but could also found in de "novo" patients (i.e. I CEBPA i [[8]] and I DDX41 i [[9]]). Three patients (50%) had extramedullary localization (nodal involvement, hepatosplenomegaly and skin lesion in 3, 2, and 1 patients respectively), compared to 11/72 (15%) for other AML patients. As we treated patients from this geographic area with familial history of AML but no personal history of MPN, we wondered if CNVdup14 could arise in " I de novo i AML" patients. Genetic predisposition to acute myeloid leukemia (AML) concerns a minority of adult patients. [Extracted from the article]

Published
2021
Full Text
View/download PDF

27. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin's lymphoma not eligible for intensive chemotherapy.

Author

Abdayem, Pamela, Ibrahim, Nathalie, El Dakdouki, Yolla, Willekens, Christophe, Ghez, David, A. Rouche, Julia, Dartigues, Peggy, Desmaris, Romain, Danu, Alina, Rossignol, Julien, Lazarovici, Julien, Fermé, Christophe, Ribrag, Vincent, and Michot, Jean M.

Subjects
LYMPHOMAS, RITUXIMAB, CYTARABINE, ETOPOSIDE, DRUG efficacy
Abstract

Objectives: To evaluate the efficacy and tolerability of an attenuated immunochemotherapy regimen based on cytarabine, etoposide and dexamethasone plus rituximab (R‐mini‐CYVE) in patients with relapsed or refractory B‐cell non–Hodgkin's lymphoma (NHL). Methods: We included pretreated adult patients with B‐cell NHL who were ineligible for high‐dose immunochemotherapy (HDT). Cytarabine and etoposide were given at four different dose levels, depending on the patient's frailty. Up to 8 cycles were administered. Results: Between 2013 and 2019, 56 patients with diffuse large B‐cell lymphoma (n = 45, 80%) and indolent B‐cell lymphoma (n = 11, 20%) were included. Median age was 75 (range: 36‐88). Nineteen patients (35%) had a performance status ≥2. Patients received a median of 4 cycles of R‐mini‐CYVE. The objective response and the complete response rates were 50% and 33%, respectively. Median progression‐free survival and overall survival times were 5.7 (95% CI: 0.5‐10.9) and 14.7 (95% CI: 3.5‐25.9) months, respectively. Grade ≥3 anaemia, thrombocytopenia and neutropenia occurred in 44%, 55% and 60% of the patients, respectively. The most frequent non‐haematological grade ≥3 adverse events were sepsis (21%), fatigue (13%) and cytarabine‐related neurotoxicity (5%). Conclusion: R‐mini‐CYVE demonstrated a meaningful antitumour efficacy and an acceptable safety profile in patients with relapsed/refractory B‐cell NHL who were ineligible for HDT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

28. Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report

Author

Wacrenier Agnès, Guerry Mary-Jane, Cornelius Aurélie, Willekens Christophe, and Fourrier François

Subjects
Medicine
Abstract

Abstract Introduction Hemophagocytic lymphohistiocytosis induced by viral diseases is a well recognized entity. Severe forms of H5N1 influenza are known to be associated with symptoms very similar to a reactive hemophagocytic syndrome. We report a case of fulminant lymphohistiocytosis associated with the pandemic A (H1N1) variant. Case presentation A 42-year-old Caucasian woman developed a syndrome of fatal hemophagocytic lymphohistiocytosis shortly after H1N1 influenza. Initial symptoms of the viral disease were unusual, with acute abdominal involvement. Our patient's course was complicated by diffuse skin rash and ileal ischemia. Our patient died of refractory shock and multi-organ failure. Skin, ileum and colon histology was consistent with an acute apoptosis combined with an increased cellular regeneration. Conclusions Influenza may be complicated by severe forms of hemophagocytic lymphohistiocytosis. To ensure early recognition and treatment, physicians should be aware of the possible induction of the syndrome by the novel H1N1 variant. The rapid occurrence of a multi-organ involvement with evocative biological features of macrophage activation should alert clinicians.

Published
2011
Full Text
View/download PDF

29. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.

Author

Hueso, Thomas, Ekpe, Kenneth, Mayeur, Camille, Gatse, Anna, Joncquel-Chevallier Curt, Marie, Gricourt, Guillaume, Rodriguez, Christophe, Burdet, Charles, Ulmann, Guillaume, Neut, Christel, Amini, Salah-Eddine, Lepage, Patricia, Raynard, Bruno, Willekens, Christophe, Micol, Jean-Baptiste, De Botton, Stéphane, Yakoub-Agha, Ibrahim, Gottrand, Frédéric, Desseyn, Jean-Luc, and Thomas, Muriel

Published
2021
Full Text
View/download PDF

30. High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result.

Author

Michot, Jean‐Marie, Annereau, Maxime, Danu, Alina, Legoupil, Clémence, Bertin, Louis, Chahine, Claude, Achab, Nadia, Antosikova, Anna, Cerutti, Ariane, Rossignol, Julien, Ghez, David, Willekens, Christophe, Dartigues, Peggy, Lazarovici, Julien, Lemare, Francois, and Ribrag, Vincent

Subjects
NON-Hodgkin's lymphoma, DIFFUSE large B-cell lymphomas, CELLULAR therapy
Abstract

Background: High‐dose cyclophosphamide to treat solid refractory tumors demonstrated meaningful activity, while data to treat lymphoma remain scarce. This study aims to assess high‐dose cyclophosphamide to treat relapsed or refractory lymphoma. Methods: A phase II study included adult patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, previously treated by ≥2 prior lines with no other available option of therapy. High‐dose cyclophosphamide was given intravenously 3 g/m2 over two consecutive days and repeated once at 28 days in responding patients. Rituximab 375 mg/m2 intravenously was added in patients not refractory to anti‐CD20 antibody. Results: Forty‐two patients with median age 65 [56‐70] years were included. Patients had previously received a median of four lines of therapies. Tumor types were diffuse large B‐cell lymphoma (n = 26; 62%), indolent B‐cell non‐Hodgkin lymphoma (n = 10; 24%), or mantle lymphoma (n = 6; 14%). Hematologic and non‐hematologic grade 3‐5 toxicities occurred in 42 (100%) and 18 (43%) of patients, respectively. The overall response rate was 45%. Conclusion: One to two cycles of high‐dose cyclophosphamide in hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma demonstrated a favorable safety and efficacy profile. This regimen could serve as a bridge to modern cellular therapy with CAR‐T cell. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Author

de Botton, Stephane, Mondesir,Johanna, Willekens,Christophe, and Touat,Mehdi

Subjects
Journal of Blood Medicine
Abstract

Johanna Mondesir1,2 Christophe Willekens3–5 Mehdi Touat6,7 Stéphane de Botton3–5 1Service d’Immunopathologie Clinique, Hôpital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Université Paris Descartes, Paris, 3Gustave Roussy, Université Paris-Saclay, Service d’Hématologie Clinique, 4INSERM U1170, Gustave Roussy, Université Paris-Saclay, Villejuif, 5Faculté de médecine Paris-Sud, Kremlin-Bicêtre, 6AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière – Charles Foix, Service de Neurologie 2-Mazarin, Paris, 7Gustave Roussy, Université Paris‑Saclay, Département d’Innovation Thérapeutique et d’Essais Précoces, Villejuif, France Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations inIDH1/2confer a gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess of an oncometabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high levels of D-2HG inhibit α-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, leading to histone and DNA hypermethylation and finally a block in cell differentiation. Furthermore, D-2HG is a biomarker suitable for the detection ofIDH1/2mutations at diagnosis and predictive of the clinical response. Finally, mutant-IDH1/2 enzymes inhibitors have entered clinical trials for patients withIDH1/2mutations and represent a novel drug class for targeted therapy. Keywords: tumor metabolism, epigenetic, oncogene, IDH1, IDH2, glioma, acute myeloid leukemia, 2-HG, targeted therapies

Published
2016

33. Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Author

Khalife-Hachem, Sabine, Saleh, Khalil, Pasquier, Florence, Tarabay, Anthony, Quivoron, Cyril, Cotteret, Sophie, Willekens, Christophe, Saada, Veronique, Vaz-Luis, Ines-Maria, Delaloge, Suzette, Leary, Alexandra, Raslova, Hana, Rosselli, Filippo, Caron, Olivier, Antony-Debre, Iléana, Solary, Eric, de Botton, Stephane, Marzac, Christophe, and Micol, Jean-Baptiste

Published
2019
Full Text
View/download PDF

34. The Impact of Risk-adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplant

Author

Sakr, Riwa, Pilorge, Sylvain, De Botton, Stephane, Chahine, Claude, Coman, Tereza, Adler, Marcel, Micol, Jean-Baptiste, Pasquier, Florence, Willekens, Christophe, Danu, Alina, Lazarovici, Julien, Ghez, David, Solary, Eric, Ribrag, Vincent, Bourhis, Jean-Henri, and Castilla-Llorente, Cristina

Published
2018
Full Text
View/download PDF

35. Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

Author

DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Roboz, Gail J., Altman, Jessica K., Mims, Alice S., Swords, Ronan, Collins, Robert H., Mannis, Gabriel N., Pollyea, Daniel A., Donnellan, Will, Fathi, Amir T., Pigneux, Arnaud, Erba, Harry P., Prince, Gabrielle T., Stein, Anthony S., Uy, Geoffrey L., Foran, James M., Traer, Elie, Stuart, Robert K., Arellano, Martha L., Slack, James L., Sekeres, Mikkael A., Willekens, Christophe, Choe, Sung, Wang, Hongfang, Zhang, Vickie, Yen, Katharine E., Kapsalis, Stephanie M., Yang, Hua, Dai, David, Fan, Bin, Goldwasser, Meredith, Liu, Hua, Agresta, Sam, Wu, Bin, Attar, Eyal C., Tallman, Martin S., Stone, Richard M., and Kantarjian, Hagop M.

Published
2018
Full Text
View/download PDF

36. Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

Author

Sakr, Riwa, Renneville, Aline, Saada, Veronique, Cotteret, Sophie, Martin, Jean-Edouard, Droin, Nathalie, Selimoglu-Buet, Dorothée, Besse, Benjamin, Hollebecque, Antoine, Marzac, Christophe, Pasquier, Florence, Micol, Jean-Baptiste, De Botton, Stéphane, Mir, Olivier, Solary, Eric, and Willekens, Christophe

Subjects
NUCLEOTIDE sequencing, MYELODYSPLASTIC syndromes, CANCER patients, PHYSIOLOGY, GENETICS
Published
2018
Full Text
View/download PDF

37. The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Author

Sakr, Riwa, Pilorge, Sylvain, De Botton, Stephane, Chahine, Claude, Coman, Tereza, Adler, Marcel, Micol, Jean-Baptiste, Pasquier, Florence, Willekens, Christophe, Danu, Alina, Lazarovici, Julien, Ghez, David, Solary, Eric, Ribbag, Vincent, Bourhis, Jean-Henri, and Castilla-LLorente, Cristina

Published
2017
Full Text
View/download PDF

38. Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Author

Willekens, Christophe, Saada, Veronique, Broutin, Sophie, Delahousse, Julia, Renneville, Aline, Petrovanu, Cynthia, Marzac, Christophe, Micol, Jean-Baptiste, Solary, Éric, Pasquier, Florence, Lazarovici, Julien, Ribrag, Vincent, Preudhomme, Claude, Quivoron, Cyril, Penard-Lacronique, Virginie, Paci, Angelo, and de Botton, Stephane

Published
2017
Full Text
View/download PDF

39. Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Author

Quek, Lynn, David, Muriel, Kennedy, Alison, Metzner, Marlen, Amatangelo, Michael, Shih, Alan H., Stoilova, Bilyana, Karamitros, Dimitris, Quivoron, Cyril, Heiblig, Mael, Willekens, Christophe, Saada, Veronique, Peniket, Andrew, Bernard, Olivier, Agresta, Sam, Yen, Katharine, Stein, Eytan M., De Botton, Stephane, Thakurta, Anjan, Levine, Ross L., Penard-Lacronique, Virginie, and Vyas, Paresh

Published
2017
Full Text
View/download PDF

41. Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.

Author

Ricard, Laure, Abisror, Noémie, Droin, Nathalie, Selimoglu-Buet, Dorothée, Martin, Antoine, Soussan, Michael, Willekens, Christophe, Deligny, Christophe, Fain, Olivier, Solary, Eric, Mekinian, Arsène, and at the behalf MINHEMON (French network of dysimmune disorders associated to hemopathies)

Subjects
RETROPERITONEAL fibrosis, LEUKEMIA, STEROIDS, AZACITIDINE, ARTHRITIS, EXTRAMEDULLARY hematopoiesis
Abstract

The article focuses on determination of retroperitoneal fibrosis (RPF) as extramedullary hematopoiesis of a chronic myelomonocytic leukemia (CMML). It mentions that CMML-associated RPF that remained unresponsive to steroids but dramatically improved upon treatment with the demethylating drug azacytidine. It states that the occurrence of an autoimmune or inflammatory disorder, mostly a vasculitis, an arthritis or a relapsing polychondritis is a well-known feature in CMML.

Published
2018
Full Text
View/download PDF

42. Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Author

Somervaille, Tim, Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Perez Simon, Jose Antonio, Pigneux, Arnaud, Recher, Christian, Popat, Rakesh, Molinero, Cesar, Mascaro, Christina, Maes, Tamara, and Bosch, Francesc

Published
2016
Full Text
View/download PDF

44. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

Author

Mondesir, Johanna, Willekens, Christophe, Touat, Mehdi, and de Botton, Stéphane

Abstract

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to a-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic cholangiocarcinomas, and hematologic malignancies. Somatic point mutations in IDH1/2 confer a gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess of an oncometabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high levels of D-2HG inhibit a-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, leading to histone and DNA hypermethylation and finally a block in cell differentiation. Furthermore, D-2HG is a biomarker suitable for the detection of IDH1/2 mutations at diagnosis and predictive of the clinical response. Finally, mutant-IDH1/2 enzymes inhibitors have entered clinical trials for patients with IDH1/2 mutations and represent a novel drug class for targeted therapy. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

48. An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type 1: Case Report.

Author

Daou, Badih, Zanello, Marc, Varlet, Pascale, Brugieres, Laurence, Jabbour, Pascal, Caron, Olivier, Lavoine, Noémie, Dhermain, Frederic, Willekens, Christophe, Beuvon, Frederic, Malka, David, Lechapt-Zalcmann, Emmanuèle, and Lahoud, Georges Abi

Published
2015
Full Text
View/download PDF

49. AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Author

Quivoron, Cyril, David, Muriel, Straley, Kim, Travins, Jeremy, Kim, Hyeryun, Chen, Yue, Zhu, Dongwei, Saada, Véronique, Bawa, Olivia, Opolon, Paule, Polrot, Mélanie, Micol, Jean-Baptiste, Willekens, Christophe, Bernard, Olivier, Yang, Hua, Agresta, Sam, de Botton, Stéphane, Yen, Katharine, and Penard-Lacronique, Virginie

Published
2014
Full Text
View/download PDF

50. AML At First Relapse: A Real Life Picture

Author

Boyle, Eileen Mary, Preudhomme, Claude, Nibourel, Olivier, Roche-Lestienne, Catherine, Morgan, Gareth J, Dupriez, Brigitte, Plantier, Isabelle, Gruson, Berengere, Marolleau, Jean Pierre, Lebon, Delphine, Fernandes, Jose, Willekens, Christophe, Quesnel, Bruno, and Berthon, Céline

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results